Literature DB >> 27269869

Alcohol intake alters immune responses and promotes CNS viral persistence in mice.

Jennifer M Loftis1, Jonathan Taylor2, Hans-Peter Raué3, Mark K Slifka4, Elaine Huang5.   

Abstract

Chronic hepatitis C virus (HCV) infection leads to progressive liver disease and is associated with a variety of extrahepatic effects, including central nervous system (CNS) damage and neuropsychiatric impairments. Alcohol abuse can exacerbate these adverse effects on brain and behavior, but the molecular mechanisms are not well understood. This study investigated the role of alcohol in regulating viral persistence and CNS immunopathology in mice infected with lymphocytic choriomeningitis virus (LCMV), a model for HCV infections in humans. Female and male BALB/c mice (n=94) were exposed to alcohol (ethanol; EtOH) and water (or water only) using a two-bottle choice paradigm, followed one week later by infection with either LCMV clone 13 (causes chronic infection similar to chronic HCV), LCMV Armstrong (causes acute infection), or vehicle. Mice were monitored for 60days post-infection and continued to receive 24-h access to EtOH and water. Animals infected with LCMV clone 13 drank more EtOH, as compared to those with an acute or no viral infection. Six weeks after infection with LCMV clone 13, mice with EtOH exposure evidenced higher serum viral titers, as compared to mice without EtOH exposure. EtOH intake was also associated with reductions in virus-specific CD8(+) T cell frequencies (particularly CD11a(hi) subsets) and evidence of persistent CNS viremia in chronically infected mice. These findings support the hypothesis that EtOH use and chronic viral infection can result in combined toxic effects accelerating CNS damage and neuropsychiatric dysfunction and suggest that examining the role of EtOH in regulating viral persistence and CNS immunopathology in mice infected with LCMV can lead to a more comprehensive understanding of comorbid alcohol use disorder and chronic viral infection. Published by Elsevier B.V.

Entities:  

Keywords:  Blood brain barrier; Ethanol; Hepatitis C virus; Lymphocytic choriomeningitis virus; Neurotoxicity; T-cells

Mesh:

Substances:

Year:  2016        PMID: 27269869      PMCID: PMC5894517          DOI: 10.1016/j.bbr.2016.06.006

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  66 in total

Review 1.  Failure of innate and adaptive immune responses in controlling hepatitis C virus infection.

Authors:  Robert Thimme; Marco Binder; Ralf Bartenschlager
Journal:  FEMS Microbiol Rev       Date:  2012-01-04       Impact factor: 16.408

Review 2.  Immunological memory and protective immunity: understanding their relation.

Authors:  R Ahmed; D Gray
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

3.  Quantitating the magnitude of the lymphocytic choriomeningitis virus-specific CD8 T-cell response: it is even bigger than we thought.

Authors:  David Masopust; Kaja Murali-Krishna; Rafi Ahmed
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

4.  Tumor-necrosis factor impairs CD4(+) T cell-mediated immunological control in chronic viral infection.

Authors:  Marc Beyer; Zeinab Abdullah; Jens M Chemnitz; Daniela Maisel; Jil Sander; Clara Lehmann; Yasser Thabet; Prashant V Shinde; Lisa Schmidleithner; Maren Köhne; Jonel Trebicka; Robert Schierwagen; Andrea Hofmann; Alexey Popov; Karl S Lang; Annette Oxenius; Thorsten Buch; Christian Kurts; Mathias Heikenwalder; Gerd Fätkenheuer; Philipp A Lang; Pia Hartmann; Percy A Knolle; Joachim L Schultze
Journal:  Nat Immunol       Date:  2016-03-07       Impact factor: 25.606

5.  Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C.

Authors:  F Pessione; F Degos; P Marcellin; V Duchatelle; C Njapoum; M Martinot-Peignoux; C Degott; D Valla; S Erlinger; B Rueff
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

6.  Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C.

Authors:  Daniele Prati; Mitchell L Shiffman; Moisés Diago; Edward Gane; K Rajender Reddy; Paul Pockros; Patrizia Farci; Christopher B O'Brien; Pilar Lardelli; Steven Blotner; Stefan Zeuzem
Journal:  J Hepatol       Date:  2006-01-25       Impact factor: 25.083

7.  Ethanol consumption modifies dendritic cell antigen presentation in mice.

Authors:  Richard Heinz; Carl Waltenbaugh
Journal:  Alcohol Clin Exp Res       Date:  2007-10       Impact factor: 3.455

8.  Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha.

Authors:  Jennifer M Loftis; Marilyn Huckans; Samantha Ruimy; David J Hinrichs; Peter Hauser
Journal:  Neurosci Lett       Date:  2007-11-06       Impact factor: 3.046

9.  Novel mechanism of arenavirus-induced liver pathology.

Authors:  Juliane I Beier; Jenny D Jokinen; Gretchen E Holz; Patrick S Whang; Amah M Martin; Nikole L Warner; Gavin E Arteel; Igor S Lukashevich
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

10.  Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review.

Authors:  Amirhossein Modabbernia; Hossein Poustchi; Reza Malekzadeh
Journal:  Hepat Mon       Date:  2013-01-07       Impact factor: 0.660

View more
  2 in total

1.  Neuroinvasion and cognitive impairment in comorbid alcohol dependence and chronic viral infection: An initial investigation.

Authors:  Jennifer M Loftis; Jonathan Taylor; Rebekah Hudson; Evan J Firsick
Journal:  J Neuroimmunol       Date:  2019-07-10       Impact factor: 3.478

2.  Heavy Alcohol Use and Age Effects on HIV-Associated Neurocognitive Function.

Authors:  Ronald A Cohen; Joseph M Gullett; Eric C Porges; Adam J Woods; Damon G Lamb; Vaughn E Bryant; Mikayla McAdams; Karen Tashima; Robert Cook; Kendall Bryant; Mollie Monnig; Christopher W Kahler; Peter M Monti
Journal:  Alcohol Clin Exp Res       Date:  2018-12-16       Impact factor: 3.455

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.